These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7664546)

  • 1. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
    Fisher CJ; Opal SM; Dhainaut JF; Stephens S; Zimmerman JL; Nightingale P; Harris SJ; Schein RM; Panacek EA; Vincent JL
    Crit Care Med; 1993 Mar; 21(3):318-27. PubMed ID: 8440099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
    Cohen J; Carlet J
    Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot clinical trial of an anti-TNF alpha monoclonal antibody for the treatment of septic shock.
    Boillot A; Capellier G; Racadot E; Wijdenes J; Herve P; Barale F
    Clin Intensive Care; 1995; 6(2):52-6. PubMed ID: 10150799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study.
    Zeni F; Pain P; Vindimian M; Gay JP; Gery P; Bertrand M; Page Y; Page D; Vermesch R; Bertrand JC
    Crit Care Med; 1996 Feb; 24(2):207-14. PubMed ID: 8605790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome.
    Gallagher J; Fisher C; Sherman B; Munger M; Meyers B; Ellison T; Fischkoff S; Barchuk WT; Teoh L; Velagapudi R
    Intensive Care Med; 2001 Jul; 27(7):1169-78. PubMed ID: 11534565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis.
    Riché FC; Cholley BP; Panis YH; Laisné MJ; Briard CG; Graulet AM; Guéris JL; Valleur PD
    Crit Care Med; 2000 Feb; 28(2):433-7. PubMed ID: 10708179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of aging on circulating levels of proinflammatory cytokines during septic shock. Norasept II Study Investigators.
    Marik PE; Zaloga GP;
    J Am Geriatr Soc; 2001 Jan; 49(1):5-9. PubMed ID: 11207836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations and anti-L-cytokine effects of alpha-melanocyte stimulating hormone in septic patients.
    Catania A; Cutuli M; Garofalo L; Airaghi L; Valenza F; Lipton JM; Gattinoni L
    Crit Care Med; 2000 May; 28(5):1403-7. PubMed ID: 10834686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardial and vascular adrenergic alterations in a rat model of endotoxin shock: reversal by an anti-tumor necrosis factor-alpha monoclonal antibody.
    Boillot A; Massol J; Maupoil V; Grelier R; Bernard B; Capellier G; Berthelot A; Barale F
    Crit Care Med; 1997 Mar; 25(3):504-11. PubMed ID: 9118669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
    Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
    Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. sTREM-1 predicts intensive care unit and 28-day mortality in cancer patients with severe sepsis and septic shock.
    Ravetti CG; Moura AD; Vieira ÉL; Pedroso ÊR; Teixeira AL
    J Crit Care; 2015 Apr; 30(2):440.e7-13. PubMed ID: 25541104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
    Rankin EC; Choy EH; Kassimos D; Kingsley GH; Sopwith AM; Isenberg DA; Panayi GS
    Br J Rheumatol; 1995 Apr; 34(4):334-42. PubMed ID: 7788147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.